Capdevila Ferran, Vera Ruth, Ochoa Patricia, Galbete Arkaitz, Sanchez-Iriso Eduardo
1 Clinical Trials Platform, Navarrabiomed, Pamplona, Spain.
2 Public University of Navarra, Pamplona, Spain.
Ther Innov Regul Sci. 2019 Sep;53(5):641-647. doi: 10.1177/2168479018809692. Epub 2018 Nov 14.
Clinical trials should be part of routine health care. There is a common perception that enrolling patients into clinical trials results in additional costs. We conducted a retrospective cost analysis to compare medical costs attributable to participation in cancer treatment trials versus standard of care in a single Spanish institution.
Patients recruited into cancer clinical trials between 2014 and 2016 were selected. Each research protocol was reviewed to identify trial-associated medical procedures and costs, as well as the equivalent care had the patient not been entered in the trial. Treatment cost difference was the difference between the cost of the clinical trial and that of the standard of care.
A total of 68 adult patients were treated in 20 different clinical trials. The overall cost treatment of the patients included in the trials was 79% lower in comparison to the standard of care. However, the load of medical procedures was 32% higher. The average treatment cost per patient and protocol ranged from an excess of €8193 to a saving of €59,770.
There is a wide range of difference in treatment costs for cancer clinical trial participants versus standard of care. Commercial trial protocols were associated with larger savings compared with the noncommercial ones, even though these may involve excess treatment costs. Overall, clinical trials provide not only the best context for progress of clinical research and health care but also creates opportunities for reducing cancer care costs.
临床试验应成为常规医疗保健的一部分。人们普遍认为,将患者纳入临床试验会带来额外成本。我们进行了一项回顾性成本分析,以比较西班牙一家机构中参与癌症治疗试验与接受标准治疗的医疗成本。
选取2014年至2016年间招募到癌症临床试验中的患者。对每个研究方案进行审查,以确定与试验相关的医疗程序和成本,以及如果患者未参加试验时的等效治疗。治疗成本差异是临床试验成本与标准治疗成本之间的差异。
共有68名成年患者参与了20项不同的临床试验。试验中患者的总体治疗成本比标准治疗低79%。然而,医疗程序负担高出32%。每位患者和每个方案的平均治疗成本从超出8193欧元到节省59770欧元不等。
癌症临床试验参与者与标准治疗的治疗成本存在很大差异。与非商业试验方案相比,商业试验方案节省的费用更多,尽管这些方案可能涉及额外的治疗成本。总体而言,临床试验不仅为临床研究和医疗保健的进展提供了最佳环境,还为降低癌症治疗成本创造了机会。